FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation

 
• By The Pink Sheet

The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation

More from Archive

More from Pink Sheet